Research programme: potassium channel blockers - Scion
Latest Information Update: 29 Aug 2007
At a glance
- Originator CeNeS Pharmaceuticals
- Class
- Mechanism of Action Potassium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Atrial fibrillation; Multiple sclerosis; Peripheral nervous system diseases; Spinal cord injuries
Most Recent Events
- 29 Aug 2007 No development reported - Preclinical for Atrial fibrillation in USA (unspecified route)
- 29 Aug 2007 No development reported - Preclinical for Multiple sclerosis in USA (unspecified route)
- 29 Aug 2007 No development reported - Preclinical for Peripheral nervous system diseases in USA (unspecified route)